Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mannkind Corp (MNKD)

Mannkind Corp (MNKD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,713,451
  • Shares Outstanding, K 307,070
  • Annual Sales, $ 285,500 K
  • Annual Income, $ 27,590 K
  • EBIT $ 73 M
  • EBITDA $ 84 M
  • 60-Month Beta 0.81
  • Price/Sales 5.47
  • Price/Cash Flow 40.42
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 249.43% (-10.95%)
  • Historical Volatility 32.29%
  • IV Percentile 73%
  • IV Rank 45.60%
  • IV High 500.78% on 10/09/25
  • IV Low 38.72% on 04/01/25
  • Expected Move (DTE 7) 0.13 (2.41%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 7,199
  • Volume Avg (30-Day) 1,526
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 75,498
  • Open Int (30-Day) 70,602
  • Expected Range 5.15 to 5.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.01
  • Number of Estimates 4
  • High Estimate 0.02
  • Low Estimate -0.07
  • Prior Year 0.03
  • Growth Rate Est. (year over year) -133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.20 +0.38%
on 01/16/26
6.51 -19.82%
on 01/08/26
-0.69 (-11.68%)
since 12/16/25
3-Month
4.93 +5.88%
on 11/18/25
6.51 -19.82%
on 01/08/26
-0.13 (-2.43%)
since 10/16/25
52-Week
3.38 +54.38%
on 08/11/25
6.51 -19.82%
on 01/08/26
-0.79 (-13.14%)
since 01/16/25

Most Recent Stories

More News
MannKind Provides Business Updates and 2026 Growth Drivers

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through...

MNKD : 5.22 (-6.45%)
MannKind Shares FUROSCIX® Business Updates

FDA approves FUROSCIX ® for use in pediatric patients weighing 43kg or above USPTO issues five patents for FUROSCIX ReadyFlow ™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON,...

MNKD : 5.22 (-6.45%)
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlowâ„¢ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and convenient...

MNKD : 5.22 (-6.45%)
MannKind to Present at the Jefferies Global Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD ) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss,...

MNKD : 5.22 (-6.45%)
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

$100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The...

MNKD : 5.22 (-6.45%)
MannKind: Q3 Earnings Snapshot

MannKind: Q3 Earnings Snapshot

MNKD : 5.22 (-6.45%)
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

Q3 2025 revenues of $82.1M, +17% v. Q3 2024 YTD 2025 revenues of $237.0M, +14% v. YTD 2024 Completed acquisition of scPharmaceuticals on October 7, accelerating MannKind’s revenue growth with FUROSCIX...

MNKD : 5.22 (-6.45%)
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that its third quarter 2025 financial results will be released before...

MNKD : 5.22 (-6.45%)
Healthcare's Shift to Prevention Gains Momentum as Markets Reach Critical Mass

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Longevity science advances reveal how genes from supercentenarians can reverse cardiac aging[1], while...

HUM : 275.48 (-2.98%)
AVAI : 0.7699 (-0.91%)
CRSP : 53.59 (-1.14%)
VRTX : 443.86 (+1.13%)
MNKD : 5.22 (-6.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder...

See More

Key Turning Points

3rd Resistance Point 5.79
2nd Resistance Point 5.73
1st Resistance Point 5.66
Last Price 5.22
1st Support Level 5.53
2nd Support Level 5.47
3rd Support Level 5.40

See More

52-Week High 6.51
Fibonacci 61.8% 5.31
Last Price 5.22
Fibonacci 50% 4.95
Fibonacci 38.2% 4.58
52-Week Low 3.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar